What Fueled TESARO Inc. Shares' 20% Mega-Surge Today

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of TESARO  (NASDAQ: TSRO  ) are trading about 22% higher today after the biotech company reported good results out of its final Phase 3 trial of Rolapitant.

So what: Rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist developed to prevent chemotherapy-related nausea and vomiting (CINV), completed its phase 3 trials for oral dosing with successful achievement of all primary and secondary endpoints. The drug managed to prevent significant nausea symptoms in all trial patients -- who had been undergoing cisplatin-based highly emetogenic chemotherapy -- in both its acute (first 24 hours) and overall (first five days) windows of dosing. The company now plans to submit a new drug application to the FDA by midyear, and rolapitant is also undergoing phase 2 trials for intravenous dosing, which will likely expand its availability in the future.

Now what: Fool health-care specialist Leo Sun has already noted that rolapitant will compete with Merck's Emend, which also treats CINV, but TESARO believes it offers advantages over the much larger company's $500-million drug. BMO Capital also sees some major upside in TESARO's shares after this news release, as it's raised its price target to $66 -- a 125% upside even after today's pop. TESARO has several cancer treatments also in development, and rolapitant's sales could provide more than enough cash flow to allow the company to move these drugs through the trial process while simultaneously developing new ones. There's a lot to like about today's news, but TESARO is still a development-stage biotech. If you plan to invest on this news, do so optimistically, but cautiously.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2953886, ~/Articles/ArticleHandler.aspx, 11/29/2014 2:45:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 17,828.24 0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASD 4,791.63 4.31 0.09%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

11/28/2014 12:59 PM
TSRO $34.51 Down -0.24 -0.69%
TESARO CAPS Rating: **

Advertisement